In the Claims:

1. (Currently Amended) A pharmaceutical composition for the treatment of fungal pathologies of the oral cavity comprising a therapeutically effective amount of a peptide selected from the group consisting of KPV (SEQ. ID. NO. 1), VPK-Ac-CC-Ac-KPV (SEQ. ID. NO. 8), and HFRWGKPV (SEQ. ID. NO. 3) having a C-terminal sequence amino acid sequence KPV (SEQ. ID. NO. 1) in combination with a therapeutically effective amount of a fungicide and wherein the fungal pathology is oral candidiasis.

2. (Canceled)

- 3. (Previously Presented) The composition of claim 1 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
- 4. (Previously Presented) The composition of claim 1 further comprising a therapeutically effective amount of an antibiotic.
- 5. (Previously Presented) The composition of claim 4 wherein said antibiotic further comprises a gram negative antibiotic.
- 6. (Previously Presented) The composition of claim 4 wherein said antibiotic further comprises a gram positive antibiotic.
- 7. (Previously Presented) The composition of claim 4 wherein said antibiotic is selected from the group consisting of: aminglycosides, amoxicillin, ampicillin,

azithramycin, erythromycin, nafcillin, penicillin, quinupuristin dalfopristin and vancomycin.

- 8. (Previously Presented) The pharmaceutical composition of claim 1 further solvated in a carrier.
- 9. (Previously Presented) The composition of claim 1 wherein the concentration of said peptide is at least 10⁻¹²M.
- 10. (Previously Presented) The composition of claim 8 wherein the carrier is selected from the group consisting of: creams, gels, mouthwashes, toothpastes, tablets, and atomized sprays.
- 11. (Currently Amended) A pharmaceutical composition for the treatment of fungal pathologies of the oral cavity comprising a therapeutically effective amount of a peptide selected from the group consisting of KPV (SEQ. ID. NO. 1), VPK-Ac-CC-Ac-KPV (SEQ. ID. NO. 8), and HFRWGKPV (SEQ. ID. NO. 3) having a C-terminal sequence amino acid sequence KPV (SEQ. ID. NO. 1) in combination with a therapeutically effective amount of a fungicide and a therapeutically effective amount of an antibiotic and wherein the fungal pathology is oral candidiasis.

12. (Canceled)

13. (Previously Presented) The composition of claim 11 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

- 14. (Previously Presented) The composition of claim 11 wherein said antibiotic further comprises a gram positive antibiotic.
- 15. (Previously Presented) The composition of claim 11 wherein said antibiotic further comprises a gram negative antibiotic.
- 16. (Previously Presented) The composition of claim 11 wherein said antibiotic is selected from the group consisting of: aminglycosides, amoxicillin, ampicillin, azithramycin, erythromycin, nafcillin, penicillin, quinupuristin dalfopristin and vancomycin.
- 17. (Previously Presented) The pharmaceutical composition of claim 11 further solvated in a carrier.
- 18. (Previously Presented) The composition of claim 11 wherein the concentration of said peptide is at least 10⁻¹²M.
- 19. (Previously Presented) The composition of claim 17 wherein the carrier is selected from the group consisting of: creams, gels, mouthwashes, toothpastes, tablets, and atomized sprays.
 - 20. (Canceled)
 - 21. (Canceled)
 - 22. (Canceled)
 - 23. (Canceled)

- 24. (Canceled)
- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)
- 28. (Canceled)